# Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

> **NCT01012167** · PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 86 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Oxytocin
- **DRUG:** Galantamine
- **OTHER:** Placebo-Oxytocin
- **OTHER:** Placebo-Galantamine

## Key facts

- **NCT ID:** NCT01012167
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012167, "Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01012167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*